Johnson & Johnson (JNJ) Sees FY13 Revs at $70.4B - $71.1B; Est. at $71.1B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Goldman Maintains Sell on Johnson & Johnson (JNJ); Drug Business Spin Still Unlikely
April 17, 2013 10:49 AM EDTGoldman Sachs maintained a Sell rating on Johnson & Johnson (NYSE: JNJ) with a price target of $80.00. Analyst Jami Rubin reiterated his view that Johnson & Johnson should consider a break up, though he does not think management will consider this option.
... More
Johnson & Johnson (JNJ) Tops Q1 EPS by 3c; Reaffirms FY EPS Outlook
April 16, 2013 7:47 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q1 EPS of $1.44, $0.03 better than the analyst estimate of $1.41. Revenue for the quarter came in at $17.5 billion versus the consensus estimate of $17.46 billion.
Johnson & Johnson still sees FY 2013 EPS $5.35-$5.45, versus the consensus of $5.40.
... More
